Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags Exatecan

Tag: exatecan

Novel Linker-Drug Technology Enables Antibody-Drug Conjugates with an Expanded Therapeutic Window

ADC Review | Editorial Team
Preclinical data from a novel, proprietary ADC technology platform being developed by ProfoundBio was being presented at the 2021 Molecular Targets and Cancer Therapeutics...

Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...

Peter Hofland
The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X